Sagimet Biosciences (SGMT) Common Equity (2022 - 2026)

Sagimet Biosciences' Common Equity history runs 5 years deep, the most recent figure standing at $102.5 million for Q1 2026.

• In Q1 2026, Common Equity fell 26.28% year-over-year to $102.5 million; the TTM figure through Mar 2026 stood at $102.5 million (down 26.28% YoY), while the FY2025 annual figure was $111.4 million, down 28.51% from the prior year.
• Common Equity was $102.5 million for Q1 2026 at Sagimet Biosciences, down from $111.4 million in the prior quarter.
• In the past five years, Common Equity ranged from a high of $190.0 million in Q1 2024 to a low of -$198.4 million in Q2 2023.
• Historically, Common Equity has averaged $34.9 million across 5 years, with a median of $106.9 million in 2025.
• The sharpest annual moves came in 2024 and 2025: Common Equity soared 198.61% in 2024, then tumbled 30.13% in 2025.
• A 5-year view of Common Equity shows it stood at -$187.0 million in 2022, then surged by 148.71% to $91.1 million in 2023, then soared by 71.09% to $155.8 million in 2024, then retreated by 28.51% to $111.4 million in 2025, then retreated by 8.01% to $102.5 million in 2026.
• The last three Common Equity figures came in at $102.5 million (Q1 2026), $111.4 million (Q4 2025), and $119.3 million (Q3 2025), per Business Quant data.